3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
2
Phase 3
1
Status
Recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Lymphoid
1
Conditions
Leukemia, Lymphocytic, Chronic, B-Cell
22
Lymphoma, Follicular
6
Lymphoma
4
Lymphoma, Non-Hodgkin
3
Neoplasms
2
Lymphoma, Large B-Cell, Diffuse
2
Lymphoma, B-Cell, Marginal Zone
2
Leukemia, B-Cell
2
Tumor Lysis Syndrome
1
Recurrence
1
Neoplasm, Residual
1
Leukemia
1
Disease
1
Chromosome 17 deletion
1
Interventions
osimertinib
1
obinutuzumab
1
midostaurin
1
flumatinib
1
fludarabine
1
Radiotherapy
1
Oxaliplatin
1
Mitoxantrone
1
Mercaptopurine
1
Leucovorin
1
Irinotecan
1
Gemtuzumab
1
Folfox protocol
1
Fluorouracil
1
Drug Therapy
1
Daunorubicin
1
Cytarabine
1
Cyclophosphamide
1
Busulfan
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 3
×
Neoplasm, Residual
×
obinutuzumab
×
Clear all
NCT05929222
2026-06-01
FIL_GAZEBO
Fondazione Italiana Linfomi - ETS
Phase 3
Recruiting
190 enrolled